alpha 1 antitrypsin

alpha 1 antitrypsin

A 54 kD glycoprotein that inhibits proteolytic enzymes (proteases),trypsin, chymotrypsin, elastases in lysosomes, plasmin, thrombin, collagenase, and others. Serum A1AT increases nonspecifically during inflammation and is a so-called acute phase reactant.
Elevated A1AT Inflammation, liver injury, increased oestrogen, pregnancy, malignancy, corticosteroid therapy.
Reduced A1AT Heterozygous A1AT deficiency, emphysema, prematurity, protein-losing disorders.
Ref range 2–4 g/L.
References in periodicals archive ?
Alpha 1 proteinase inhibitor is intended for therapy of congenital alpha 1 antitrypsin deficiency, which leads to emphysema.
It is estimated that there are 60,000 to 100,000 Americans with severe alpha 1 antitrypsin deficiency.
Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for pi type Z.
Ongoing Phase II Trial Tests Ability to Deliver Sustainable Treatment in Patients with Alpha 1 Antitrypsin Deficiency (AAT) Using Proprietary AAV Technology
Applied Genetic Technologies Corporation, a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that it has received a grant of $1 million from the Food and Drug Administration (FDA Orphan Drugs Program) to fund a Phase II Human Clinical Trial evaluating the safety and efficacy of a treatment for Alpha 1 Antitrypsin Deficiency (AAT), a genetic disease known to result in serious lung and/or liver disease.
Stakeholder Opinions: Alpha 1 Antitrypsin Deficiency
Assess the potential for new drugs and their potential for additional usesGain an understanding of some of the principal challenges in the treatment of alpha 1 antitrypsin deficiency as defined by key opinion leaders.
com/reports/c83288) has announced the addition of Datamonitor's new report "Stakeholder Opinions: Alpha 1 Antitrypsin Deficiency" to their offering.
In addition to the ATryn(R) program, GTC is developing a recombinant human albumin, a recombinant human alpha 1 antitrypsin, a malaria vaccine, and a CD137 antibody to stimulate the immune system as a potential treatment for solid tumors.
Other recombinant human plasma proteins that GTC is developing include recombinant human albumin and recombinant human alpha 1 antitrypsin.
Nasdaq:INHL) announced today it has been issued US patent 5,993,783 on a method for delivering an inhaleable formulation of alpha 1 antitrypsin proteinase inhibitor.
The patent covers a method for delivering aerosol dry powder alpha 1 antitrypsin proteinase inhibitor in the particle size range needed for deep lung delivery.